Sequent Scientific Limited announced that the Hon’ble National Company Law Tribunal (NCLT), Hyderabad Bench, has on November 18, 2025, allowed the petition and pronounced the order sanctioning the Composite Scheme of Amalgamation. The written order from the NCLT is awaited. The Appointed Date of the Scheme is April 1, 2025. This merger involves Sequent Scientific Limited, Symed Labs Limited, Vandana Life Sciences Private Limited, Appcure Labs Private Limited, Vindhya Pharma (India) Private Limited, S.V. Labs Private Limited, Vindhya Organics Private Limited, Viyash Life Sciences Private Limited, Geninn Life Sciences Private Limited, and Sequent Research Limited. The merger is poised to create a global animal health powerhouse, aligning to capitalize on: * Global, fast-growing Companion (Pet) Animal Health segment. * Genericization of Animal Health, leveraging technical strengths in APIs and Formulations. Key combined financial performance (Pro forma unaudited) for Q2 FY26 (quarter ended September 30, 2025): * Revenues: ₹8,521 million (₹852.1 crore), a 16% year-on-year (YoY) increase. * EBITDA: ₹1,890 million (₹189 crore), surging 76% YoY. * EBITDA margin: 22.2%, up 750 basis points YoY. Key combined financial performance (Pro forma unaudited) for H1 FY26: * Revenues: ₹16,462 million (₹1,646.2 crore), a 12.6% YoY increase. * EBITDA: ₹3,180 million (₹318 crore), up 48% YoY. * EBITDA margin: 19.3%, up 460 basis points YoY. * Net Debt to LTM EBITDA: 0.7x. Dr. Haribabu Bodepudi, Founder and CEO of Viyash, stated that the merger creates a platform for world-class solutions, leveraging strengths in R&D, custom development, manufacturing, and a streamlined supply chain. Mr. Rajaram Narayanan, Managing Director and CEO of SeQuent, expressed pleasure at the NCLT approval, highlighting the company's unique position to build a world-class business and deliver quality care for animals. The company also shared an updated Investor Presentation.
